Bluejay Diagnostics closes $8.75M public offering to repay debt and fund FDA work

Bluejay Diagnostics, Inc.

Gross proceeds $8.75M from sale of 5,368,098 units at $1.63/unit.
Units consist of 1 share (or pre-funded warrant), 2 Class C warrants, 1 Class D warrant.
Net proceeds to repay $2.3M debt and fund FDA approval (incl. clinical studies), R&D, working capital.
Class C warrants ($1.96 strike, 5-year term) require stockholder approval to become exercisable.
Underwriting discount 8.5%; Aegis Capital Corp. acted as sole underwriter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.